Abstract
The pharmaceutical (pharma) industry dominates the healthcare sector with a market capitalization of $2.7 trillion, while the biotechnology (biotech) industry is a significant component of the sector with a market capitalization of $863 billion. Both industries focus on the discovery, development, manufacturing and sale of prescription drugs, and have drivers that are both similar and unique to the industries. These include a focus on innovation and patents, drug licensing and a significant regulatory and political environment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
US Congress, Office of Technology Assessment, Pharmaceutical R&D: Costs Risks and Rewards, OTA-M-522, Washington, DC: US Government Printing Office, February 1993.
DiMasi, J and Grabowski, H. The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial And Decision Economics 28: 469–479, 2007.
DiMasi, J, Hansen, R, and Grabowski, H. The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22, 151–185, 2003.
DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L., 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10, 107–142.
Stewart, J. Allison, P. and Johnson, R. Putting a price on biotechnology, nature biotechnology, Volume 19 Sept 2001.
MIT Roundtable on Corporate Risk Management, Journal of Applied Corporate Finance, Volume 20 Number 4 Fall 2008.
Myers, S. and Shyam-Sunder, L. Measuring pharmaceutical industry risk and the cost of capital, in Helms, R.B. (ed.) Competitive Strategies in the Pharmaceutical Industry, Washington, DC, American Enterprise Institute Press, 1996.
Lütolf-Carroll, C, From Innovation to Cash Flows, Wiley, 2009.
Kellogg, D. and Charnes, J.M. Real options valuation for a biotechnology company, Financial Analysts Journal, May/June 2000.
Kelly, M, Teufel, S, Fisher Investments on Health Care, Wiley, 2011.
Myers, S. C., Howe, C. D., A Life Cycle Financial Model of Pharmaceutical R&D, Program On the Pharmaceutical Industry, MIT, 1997.
Paul, S, Mytelka, D, Dunwiddie, C, Persinger, C, Munos, B, Lindborg, S and Schacht, A. How to improve R&D productivity: the pharmaceutical industry’s grand challenge, Nature Reviews Drug Discovery 9, 203–214, 2010.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 The Author(s)
About this chapter
Cite this chapter
Rogers, J. (2019). Pharmaceuticals and Biotechnology. In: Strategy, Value and Risk. Global Financial Markets. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-030-21978-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-21978-9_9
Published:
Publisher Name: Palgrave Macmillan, Cham
Print ISBN: 978-3-030-21977-2
Online ISBN: 978-3-030-21978-9
eBook Packages: Economics and FinanceEconomics and Finance (R0)